Page 14 - Sofinnova Partners News Today

/PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of...

Company has raised $112m in order to develop therapies for central nervous system disorders - News - PharmaTimes

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Sofinnova Partners created and seed financed Noema in 2019 to advance clinical assets in-licensed from Roche This milestone underscores Sofinnova's ability to form, build and grow companies around

MUNICH, GERMANY / ACCESSWIRE / March 6, 2023 / EBD Group is thrilled to reunite on March 20-22, 2023 in Basel, Switzerland. After being held digitally for the last three years, leading executives from

EQS-News: EBD Group / Key word(s): Conference BIO-Europe Spring® 2023 is only a few weeks away 06.03.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE BIO-Europe Spring® 2023 is only a few weeks away Munich, Germany – March 6, 2023. EBD Gr...

GV led Chroma Medicines Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.

/PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!